朗生醫藥(00503.HK)中期純利9644萬美元 同比增長1916.3%
格隆匯8月27日丨朗生醫藥(00503.HK)公告,截至2020年6月30日止6個月,公司收入2677.6萬美元,同比增長2.4%;毛利1793萬美元,同比增長11.4%;公司擁有人應占溢利9644萬美元,同比增長1,916.3%;每股盈利24.3美仙。
上半年醫藥分部的收入約為2560萬美元,較去年上升5.0%,其中自有專科藥產品(包括帕夫林、新適確得)較去年同期上升20.5%。受自有專科藥產品(帕夫林及新適確得)的銷售佔比上升及毛利率上升,及同期線下銷售及分銷活動減少而使銷售及分銷開支較去年同期有所下降的多重影響,上半年醫藥分部利潤較去年同期上升48.1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.